Visceral Metastasis Articles

Visceral metastasis (VM), an important poor prognostic factor of prostate cancer (PC), is not commonly observed in castration sensitive status but is often observed after castration-resistant progression.

There is limited pooled data showing the impact of visceral metastasis on oncologic outcomes in metastatic prostate cancer (mPCa) patients treated with combination systemic therapies. We aimed to analyze and compare the efficacy of combination systemic therapies in metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) with or without visceral metastasis.

Several programmed death ligand-1 (PD1/L1) immune checkpoint inhibitors (ICIs) are approved in urothelial carcinoma (UC).

To address the need for predictors of the efficacy of ICIs in metastatic urothelial carcinoma (mUC), randomized controlled trials of PD1/L1 inhibitors alone or in combination with chemotherapy in this patient population were systematically reviewed, and differences in ICI-associated survival outcomes according to available baseline variables were quantitatively assessed.

To explore the genomic features of bone-only metastasis (bmPCa), hepatic metastasis (hmPCa) and pulmonary metastasis without liver involvement (pmPCa) in prostate cancer (PCa) using targeted next-generation sequencing.